ACD Proposed National Center for Advancing Translational Sciences Working Group

Mission and Charge

The proposed National Center for Advancing Translational Sciences (pNCATS) Working Group of the ACD has the following charge:

  • Identify specific areas and activities whereby NIH can substantially contribute to streamlining therapeutic and diagnostic development nationally and globally;
  • Recommend possible ways in which pNCATS can maximally tap the strengths of extant programs, the authorities under CAN, and the vast capabilities of potential partners;
  • Propose new models for how pNCATS could build partnerships with external entities, including biotechnology and pharmaceutical companies, to achieve its mission of accelerating translational research;
  • Recommend the subset of scientific and technical challenges along the drug discovery pipeline that pNCATS should address;
  • Recommend potential areas of translational research that fall outside the drug development process that pNCATS should consider addressing; and
  • Suggest a framework for metrics and timelines by which success of pNCATS can be measured.

Working Group Reports

Roster

  • Maria C. Freire, Ph.D. (Chair)
    President
    Albert and Mary Lasker Foundation
  • Julian Adams, Ph.D.*
    President of Research and Development
    Infinity Pharmaceuticals, Inc.
  • Lee E. Babiss, Ph.D.*
    Executive Vice President of Global Laboratory Services
    PPD, Inc.
  • Brook Byers, M.B.A.
    Senior Partner
    Kleiner Perkins Caufield & Byers
  • William W. Chin, M.D.*
    Executive Dean for Research
    Harvard Medical School
  • Susan Desmond-Hellmann, M.D., M.P.H.*
    Chancellor
    University of California, San Francisco
  • David Ginsburg, M.D.*
    James V. Neel Distinguished University Professor of Internal Medicine & Human Genetics
    University of Michigan
  • Victoria Hale, Ph.D.
    Chief Executive Officer
    Medicines360
  • Helen H. Hobbs, M.D.
    Director of the McDermott Center
    University of Texas at Southwestern
  • Robert S. Langer, Sc.D.
    David H. Koch Institute Professor
    Massachusetts Institute of Technology
  • Stelios Papadopoulos, Ph.D.
    Director and Chairman of the Board
    Exelixis
  • Mary K. Pendergast, J.D.
    President
    Pendergast Consulting
  • Moncef Slaoui, Ph.D.*
    Chairman of Research & Development
    GlaxoSmithKline
  • Marc Tessier-Lavigne, Ph.D.
    President
    Rockefeller University
  • David L. Valle, M.D.*
    Professor and Director of the Institute of Genetic Medicine
    Johns Hopkins University School of Medicine

This page last reviewed on February 12, 2011